Annexon

Annexon is developing a pipeline of novel therapeutics that inhibit the classical complement pathway by targeting C1q, aiming to address diseases driven by aberrant complement activation. Its lead programs are in clinical development for autoimmune, neurodegenerative, and ophthalmic conditions, with a focus on diseases where C1q-mediated inflammation and synaptic pruning are implicated. The company's strategy is to validate its platform through these clinical programs and expand into additional indications with high unmet medical need.

Platform focused on inhibiting the classical complement pathway at its initiation point (C1q) to treat diseases driven by inflammation and synaptic pruning.

15 drugs in pipeline, 3 in Phase 3

Annexon competes with companies targeting downstream complement components (e.g., AstraZeneca/Alexion on C5, Apellis/Astellas on C3). Its key differentiation is upstream inhibition of C1q, which may offer a more targeted mechanism with a potentially improved safety profile by preserving beneficial functions of other complement pathways.